CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
持续性血细胞减少合并活动性感染患者 CAR-T 细胞治疗后的异基因 CD34(+) 筛选造血干细胞回输
英文原题：Allogeneic CD34(+) selected hematopoietic stem cell boost following CAR T-cell therapy in a patient with prolonged cytopenia and active infection.
查看英文原题
Allogeneic CD34(+) selected hematopoietic stem cell boost following CAR T-cell therapy in a patient with prolonged cytopenia and active infection.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
血液学毒性（血液毒性）导致的外周血细胞减少是使用CD19-嵌合抗原受体（CD19-CAR）T细胞疗法后常见的长期不良反应。然而，对于CAR-T 细胞输注后1个月以上血细胞减少持续存在的患者，管理仍不明确。我们报告了一例21岁患者，因单倍体移植后复发接受CD19-CAR-T 细胞治疗。他出现了血液毒性，并因此发生多重危及生命的感染。我们给予其来自移植供者的CD34+造血干细胞支持（HSCB），导致造血恢复和感染消退，且对CD19-CAR-T 细胞活性没有任何影响。CD34+ HSCB可能是治疗CD19-CAR-T 细胞疗法后血液毒性的一种安全有效的选择。
展开英文摘要原文
Hematological toxicity (hematotoxicity) leading to peripheral cytopenias is a common long-term adverse effect following the use of CD19-chimeric antigen receptor (CD19-CAR) T-cell therapies.
However, management remains unclear for patients whose cytopenias persist beyond 1 month after CAR T-cell infusion.
We present the case of a 21-year old who received CD19-CAR T-cell therapy for relapse following a haploidentical transplant. He developed hematotoxicity and consequently multiple life-threatening infections.
We administered a CD34 + hematopoietic stem cell boost (HSCB) from his transplant donor, which led to hematopoietic recovery and resolution of his infections without any effect on the activity of CD19-CAR T cells. CD34 + HSCB can be a safe and effective option to treat hematotoxicity following CD19-CAR T-cell therapy.
论文信息
- 作者
- Lipsitt A、Beattie L、Harstead E、Li Y、Goorha S、Maron G、Gottschalk S、Triplett B
- 单位
- Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.United States
- 文献类型
- 病例报告
- 期刊
- Pediatric blood & cancer2023 Mar
- 原文标识
- PubMed 36565276 · DOI 10.1002/pbc.30166